Search Result

Results for "

MM1.S

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Casein Kinase (1) Epigenetic Reader Domain (3) FLT3 (1) HDAC (3) Histone Demethylase (4) IAP (1) IKZF Family (1) JAK (1) Ligands for E3 Ligase (2) Molecular Glues (4) Monoamine Oxidase (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PROTACs (4) Proteasome (1) SOD (1)
By Research Areas:	Cancer (21) Inflammation/Immunology (1) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147158

ZXH-1-161	Molecular Glues Ligands for E3 Ligase	Cancer
ZXH-1-161 is a potent cereblon (CRBN) modulator with an IC₅₀ value of 39 nM in MM1.S wild type cells. ZXH-1-161 has selective degradation activity towards GSPT1. ZXH-1-161 can be used for researching multiple myeloma ^[1].

HY-132857A

ZXH-4-130 TFA 1 Publications Verification	PROTACs	Neurological Disease
ZXH-4-130 TFA is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC). ZXH-4-130 TFA induces ~80% CRBN degradation at 10 nM in MM1.S cells ^[1].

HY-145667

Biotinylated-JQ1 1 Publications Verification Biotin-JQ1	Epigenetic Reader Domain	Cancer
Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of BRD4. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC₅₀ of 0.4 μM ^[1].

HY-161101

MG degrader 1	PROTACs IKZF Family	Cancer
MG degrader 1 (Compd E14) is a PROTAC degrader of IKZF3, *GSPT1, and GSPT2* with an EC₅₀ value of 1.385 nM in MM.1S cells ^[1].

HY-149924

CST626	PROTACs IAP	Cancer
CST626 (Compound 9) is a pan-IAP degrader PROTAC. CST626 degrades XIAP, cIAP1 and cIAP2 with DC₅₀s of 0.7, 2.4, and 6.2 nM in MM.1S cells, respectively ^[1].

HY-115445

LCS-1 1 Publications Verification	Apoptosis SOD	Cancer
LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC₅₀ value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells ^[1] .

HY-145322

TMX-4116	Casein Kinase Molecular Glues	Cancer
TMX-4116 is a casein kinase 1α (CK1α) degrader. TMX-4116 shows the degradation preference for CK1α with DC₅₀s less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4116 can be used for the research of multiple myeloma ^[1].

HY-125051

SG3-179	JAK FLT3	Cancer
SG3-179 is a potent inhibitor against the BET bromodomain proteins. SG3-179 is also a JAK2 and FLT3 inhibitor. SG3-179 causes a rapid reduction in HOXB13 protein expression. SG3-179 is promising for research of multiple myeloma (MM1.S) ^[1] .

HY-157216

HDAC1 Degrader-1	HDAC	Cancer
HDAC1 Degrader-1 (compound 1a) is an *HDAC1* degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells ^[1].

HY-144369

Proteasome-IN-4	Proteasome	Cancer
Proteasome-IN-4 is an excellent and non-covalent proteasome inhibitor (IC₅₀=8.39 nM). Proteasome-IN-4 has potent antiproliferative activities against RPMI-8226, MM-1S and MV-4-11 cell lines. Proteasome-IN-4 can be used for cancer research ^[1].

HY-145321

TMX-4100	Phosphodiesterase (PDE) Molecular Glues	Cancer
TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC₅₀ values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma ^[1].

HY-155671

HDAC6-IN-18	HDAC	Cancer
HDAC6-IN-18 (Compound 4) is a first irreversible HDAC6 isoform selective inhibitor with potent anti-multiple myeloma activity. HDAC6-IN-18 has HDAC6 inhibitory activity in RPMI8266, U266 and MM.1S cells with IC₅₀ values of 0.17, 0.7 and 0.42 μM, respectively ^[1].

HY-102047

KDOAM-25	Histone Demethylase	Cancer
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells ^[1].

HY-102047A

KDOAM-25 trihydrochloride	Histone Demethylase	Cancer
KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells ^[1].

HY-102047B

KDOAM-25 citrate 4 Publications Verification	Histone Demethylase	Cancer
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells ^[1].

HY-144763

XPO1-IN-1	Apoptosis	Cancer
XPO1-IN-1 (compound D4) is an orally active and potent *XPO1* inhibitor, with an IC₅₀ of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research ^[1].

HY-164099

LSD1/HDAC6-IN-2	HDAC Monoamine Oxidase Histone Demethylase	Cancer
LSD1/HDAC6-IN-2 (JBI-802) is an orally active *LSD1/HDAC6/MAO-A* inhibitor, with IC₅₀ values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma ^[1] .

HY-161250

Pomalidomide-NH-PEG6-amide-C2-CPI-1612	PROTACs	Cancer
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC₅₀ of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells ^[1].

HY-150683

NC-III-49-1	Epigenetic Reader Domain	Cancer
NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K_d values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively. NC-III-49-1 shows antiproliferative activity. NC-III-49-1 decreases the expression of c-Myc ^[1].

HY-150684

GXH-II-052	Epigenetic Reader Domain	Cancer
GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. GXH-II-052 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with K_d values of 28, 9.1, 4.8, 0.6, 8.4, 2.6 nM, respectively. GXH-II-052 shows antiproliferative activity. GXH-II-052 decreases the expression of c-Myc ^[1].

HY-118266

BTdCPU 1 Publications Verification	Phosphatase Apoptosis	Cancer
BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma ^[1] .

HY-101291

Iberdomide Maximum Cited Publications 8 Publications Verification CC-220	Ligands for E3 Ligase Apoptosis Molecular Glues	Inflammation/Immunology Cancer
Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC₅₀ of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities ^[1] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

MM1.S

Inhibitors & Agonists